Core Insights - Atara Biotherapeutics has received FDA clearance for an Investigational New Drug (IND) application for ATA3219, a novel allogeneic CAR T-cell therapy targeting systemic lupus erythematosus (SLE) with kidney involvement [1][2] - The company aims to address the unmet medical need in lupus nephritis through a Phase 1 clinical trial, which will evaluate the safety and preliminary efficacy of ATA3219 [2][3] Company Overview - Atara Biotherapeutics specializes in T-cell immunotherapy, focusing on developing off-the-shelf therapies for cancer and autoimmune diseases [1][7] - The company has extensive clinical experience, having treated over 600 patients with its allogeneic T-cell platform [2][6] - Atara is the first company to receive regulatory approval for an allogeneic T-cell immunotherapy, emphasizing its innovative approach [7] Product Details - ATA3219 is designed as a one-time infusion therapy that utilizes allogeneic Epstein-Barr virus (EBV) sensitized T cells expressing a CD19 CAR construct [5][6] - The therapy aims to provide a best-in-class profile with off-the-shelf availability, reducing the need for leukapheresis and long waiting times associated with autologous therapies [3][5] - Early academic data showed promising results, with 100% of lupus nephritis patients achieving drug-free, durable remission using autologous CD19 CAR T therapy [3][9] Clinical Trial Information - The Phase 1 trial will be a multi-center, open-label, single-arm, dose-escalation study, with subjects receiving lymphodepletion treatment followed by varying doses of ATA3219 [2][3] - The first patient is expected to be enrolled in the second half of 2024, with each dose level designed to enroll 3-6 patients [2][3] Market Context - Lupus nephritis is a serious complication of systemic lupus erythematosus, affecting over 200,000 patients in the U.S., with up to 60% of adult SLE patients developing renal disease [4] - Current therapies for lupus nephritis have suboptimal responses and limitations, highlighting the need for innovative treatments like ATA3219 [3][4]

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with ...

Core Viewpoint - Atara Biotherapeutics (NASDAQ:ATRA) is a commercial-stage biotech focused on cell therapies for Epstein-Barr virus-related diseases and cancer, showing potential for valuation appreciation despite recent trial failures and cash burn uncertainties [1] Pipeline Overview - The most advanced product, Tabelecleucel (tab-cel), is an allogeneic CAR T-cell therapy targeting EBV, approved for EBV-associated PTLD in Europe, with an FDA application planned for Q2 2024 [2][3] - Tab-cel demonstrated a 51.2% response rate and an 84.4% one-year overall survival rate in patients with EBV-positive PTLD [3] - Pierre Fabre will take over tab-cel's global development and commercialization, providing ATRA with upfront cash and future milestone payments [3] Product Development - ATA188, another EBV-directed T cell therapy for multiple sclerosis, failed its phase 2 EMBOLD study, showing only a 6% improvement in disability compared to a prior 33% reduction in phase 1 [4] - ATA3219, targeting CD19, is in early development with an IND cleared for studies in non-Hodgkin's lymphoma and systemic lupus, but no clinical data is available yet [5] Financial Overview - ATRA reported $118.7 million in total current assets, including $64.8 million in cash and equivalents, and recognized $2.1 million in revenues [6] - Total operating expenses were $71.8 million, resulting in a net loss of $69.8 million for the quarter [6] - The company received $15 million from a direct offering and $27 million from the agreement with Pierre Fabre, which may extend their cash runway [7] Strengths and Risks - Strengths include revenues from an approved product and a significant partnership with Pierre Fabre, which could drive revenue growth as tab-cel sales expand [8] - Risks involve uncertainty regarding cash runway and the lack of late-stage drugs in the pipeline, particularly after the failure of the MS drug [9][10] Bottom-Line Summary - ATRA's market cap of $122 million presents potential for significant upside if cash burn can be managed effectively, with opportunities for trial wind-downs, increasing sales, and new approvals for tab-cel [11]

Core Insights - Atara Biotherapeutics and Pierre Fabre Laboratories announced significant results from the Phase 3 ALLELE study of tab-cel, showing a 51.2% objective response rate and a median duration of response of 23.0 months in patients with relapsed or refractory EBV+ PTLD [1][2][3] Group 1: Clinical Data - The ALLELE study met its primary endpoint with 22 out of 43 patients achieving an objective response, translating to a 51.2% objective response rate [2][3] - Responders had an estimated one-year overall survival of 84.4% compared to 34.8% for non-responders, with a median overall survival of 18.4 months [2][3] - The therapy was well tolerated, with no reports of serious adverse events such as tumor flare reactions or graft-versus-host disease [2][3] Group 2: Regulatory and Market Developments - Tab-cel has received marketing authorization in the EU under the brand name EBVALLO® for patients aged two years and older with r/r EBV+ PTLD [4][5] - Atara plans to submit a biologics license application (BLA) to the FDA in Q2 2024 based on the strong clinical data [1][4] - The company has expanded its partnership with Pierre Fabre for global commercialization of tab-cel, enhancing its market reach [5][6] Group 3: Industry Context - The ALLELE study results highlight the urgent need for effective treatments for patients with limited options and poor survival rates in the r/r EBV+ PTLD population [4][6] - The innovative nature of tab-cel has been recognized, contributing to its potential as a first-in-class therapy for this patient group [6]

Core Insights - Atara Biotherapeutics and Pierre Fabre Laboratories announced the publication of pivotal Phase 3 ALLELE study data for tab-cel, a treatment for EBV+ PTLD, in The Lancet Oncology [1][2] Group 1: Study Results - The ALLELE study met its primary endpoint with an objective response rate (ORR) of 51.2%, as 22 out of 43 patients achieved an objective response [2][3] - Responders had a one-year overall survival rate of 84.4% compared to 34.8% for non-responders, with a median duration of response of 23.0 months and median overall survival of 18.4 months [2][3] - An updated analysis showed a statistically significant ORR of 49% and consistent durability of response [3] Group 2: Regulatory and Commercial Developments - Tab-cel received marketing authorization in the EU as EBVALLO™ for patients aged two years and older with r/r EBV+ PTLD [4] - Atara plans to submit a biologics license application (BLA) to the FDA in Q2 2024 for tab-cel [4] - A global partnership with Pierre Fabre Laboratories was expanded to cover the U.S. and other global markets for tab-cel [5] Group 3: Clinical Significance - The ALLELE study results highlight the life-saving potential of tab-cel for patients with limited treatment options and poor overall survival [4] - The treatment is recognized for its innovative nature, having received the Prix Galien prize in France [6]

Core Viewpoint - Atara Biotherapeutics, Inc. has announced a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a price of $0.55 per share, aiming to raise approximately $15 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable upon issuance [1]. - The offering is expected to close on or about January 10, 2024, subject to customary closing conditions [1][2]. - The securities are being offered under a shelf registration statement previously filed with the SEC, which was declared effective on November 13, 2023 [2]. Group 2: Company Overview - Atara Biotherapeutics is focused on T-cell immunotherapy, utilizing its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for cancer and autoimmune diseases [1][4]. - The company is recognized for being the first to receive regulatory approval for an allogeneic T-cell immunotherapy, highlighting its innovative approach in the field [4]. - Atara's EBV T-cell platform does not require T-cell receptor or HLA gene editing, allowing for a diverse portfolio of investigational therapies targeting EBV and next-generation AlloCAR-Ts [4].

Financial Data and Key Metrics Changes - Atara Biotherapeutics reported a cash position of approximately $102 million as of September 30, 2023, which is expected to fund operations into Q3 2025 [11] - The strategic restructuring is anticipated to reduce planned cash expenditures by approximately 40% or $100 million by the end of 2025 [10] Business Line Data and Key Metrics Changes - The expanded partnership with Pierre Fabre Laboratories for tab-cel is expected to generate up to $640 million in additional consideration, including $30 million at deal closing and $100 million in potential regulatory milestone payments [8][9] - Tab-cel is projected to have U.S. peak sales potential of over $500 million per year following potential label expansion [10] Market Data and Key Metrics Changes - The partnership with Pierre Fabre aims to commercialize tab-cel in the U.S. and other global markets, leveraging their successful launch experience in Europe [7][8] - The pricing potential for tab-cel is based on its value for patients and healthcare systems, with a listed price in Europe of approximately $640,000 [28] Company Strategy and Development Direction - Atara is transitioning to focus on developing innovative allogeneic T cell therapies for cancer and autoimmune diseases, with a strategic restructuring that includes a 30% workforce reduction [10][11] - The company is prioritizing clinical development for ATA188 and ATA3219, with anticipated clinical milestones in the near term [6][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming EMBOLD data readout for ATA188, which is expected to provide insights into its potential impact on progressive multiple sclerosis [14][20] - The company is optimistic about the regulatory process for tab-cel, with a BLA submission expected in Q2 2024 [12][46] Other Important Information - The partnership with Pierre Fabre is seen as a pivotal transition for Atara, allowing the company to focus on its pipeline while reducing cash burn [7][10] - Atara is exploring the potential of CAR-T therapies for autoimmune diseases, indicating a broader application of their technology beyond oncology [18][19] Q&A Session Summary Question: Rationale for choosing Pierre Fabre as a partner - The decision was based on financial aspects, commitment level, and the ease of managing a single partner [22][24] Question: Breakdown of the $500 million peak sales potential - The peak sales figure is linked to various indications, with a significant portion expected from the first indication of EBV+ PTLD [25][28] Question: Update on the tab-cel regulatory process - New clinical data will be included in the BLA submission, with a focus on cleaning and analyzing data from the pivotal ALLELE study [30][32] Question: Commercial plans for ATA188 - Future plans may involve strategic co-development partnerships, particularly in the U.S. market [34][37] Question: Magnitude of royalties from Pierre Fabre - The agreement includes significant double-digit tiered royalties, but specific details cannot be disclosed [39] Question: Go/no-go decision criteria for EMBOLD data - A significant statistical result or strong trend supported by additional clinical measures could lead to advancing into Phase III trials [40][43]

Financial Performance - Total current assets decreased from $295,080,000 as of December 31, 2022, to $118,696,000 as of September 30, 2023, representing a decline of approximately 60%[18] - Cash and cash equivalents decreased from $92,942,000 to $64,791,000, a reduction of about 30%[18] - The accumulated deficit increased from $1,693,024,000 to $1,908,700,000, indicating a loss of approximately $215,676,000[19] - Total revenue for the three months ended September 30, 2023, was $2,138,000, compared to $4,459,000 for the same period in 2022, representing a decrease of 52.0%[22] - Net loss for the three months ended September 30, 2023, was $(69,797,000), compared to $(84,091,000) for the same period in 2022, showing an improvement of 16.0%[22] - The company reported a comprehensive loss of $(69,435,000) for the three months ended September 30, 2023, compared to $(84,432,000) for the same period in 2022, indicating a reduction of 17.7%[22] - Net loss for the nine months ended September 30, 2023, was $215.676 million, compared to a net loss of $153.730 million for the same period in 2022, representing an increase of 40.3%[26] - Total revenue for the three and nine months ended September 30, 2023, was $2.1 million and $4.3 million, respectively, down from $4.5 million and $63.4 million in the same periods of 2022[148] Expenses and Liabilities - Total liabilities decreased from $249,780,000 to $239,626,000, a decline of about 4.6%[17] - The company reported a total stockholders' equity deficit of $50,838,000 as of September 30, 2023, compared to a positive equity of $126,640,000 at the end of 2022[19] - Research and development expenses for the nine months ended September 30, 2023, totaled $175,185,000, down from $210,018,000 in the same period of 2022, a decrease of 16.6%[22] - Total costs and operating expenses for the three months ended September 30, 2023, were $71,750,000, down from $89,081,000 in the same period of 2022, a decrease of 19.4%[22] - General and administrative expenses were $12.2 million and $39.5 million for the three and nine months ended September 30, 2023, compared to $18.9 million and $58.3 million in the same periods of 2022, reflecting lower payroll and related costs[159] Cash Flow and Financing - The company has incurred significant operating losses since inception and expects that existing cash and short-term investments will not be sufficient to fund operations for at least the next twelve months[34] - The company plans to secure additional capital through public or private security offerings and strategic transactions to alleviate concerns about its ability to continue as a going concern[35] - Net cash used in operating activities decreased to $142.571 million for the nine months ended September 30, 2023, from $213.550 million in the same period of 2022, a reduction of 33.2%[26] - The company expects its existing cash and anticipated payments will fund operations into the third quarter of 2025, but uncertainties could materially impact this cash runway[175] - The company plans to raise additional capital through equity offerings, debt financings, and strategic collaborations, which may lead to substantial dilution for existing shareholders[179] Product Development and Commercialization - The commercialization of tab-cel (Ebvallo™) is expected to expand in the UK and EU, with potential milestone and royalty payments under the amended agreement with Pierre Fabre Medicament[11] - The company is focused on advancing its clinical studies for product candidates ATA188 and ATA3219, with expectations for regulatory submissions in the near future[11] - The most advanced T-cell immunotherapy program, tab-cel® (tabelecleucel), has received marketing authorization approval in the EU and UK, and is currently in Phase 3 development in the US[30] - The company has a robust pipeline including ATA188 in Phase 2 development for multiple sclerosis and ATA3219 in preclinical development targeting B-cell malignancies[115] - The company plans to submit the tab-cel BLA in Q2 2024, following a pre-BLA meeting with the FDA in Q1 2024, to incorporate pivotal data from the Phase 3 ALLELE study[125] Revenue Generation and Collaborations - The company has out-licensed commercialization rights for Ebvallo to Pierre Fabre and sold royalty and milestone interests to HCRx, impacting revenue generation[192] - License and collaboration revenue from the early access program for the nine months ended September 30, 2023, was $0.6 million, down from $1.6 million in the same period of 2022[61] - The company received a total investment of $31.0 million from HCR Molag Fund, L.P. in exchange for tiered sales-based royalties for Ebvallo, capped between 185% and 250% of the investment amount[124] Risks and Future Outlook - The company anticipates continued losses as it develops and seeks regulatory approvals for its product candidates[175] - The company faces risks related to the successful completion of clinical studies and obtaining regulatory approvals, which are critical for future profitability[204] - The company may require substantial additional financing to achieve its goals, with uncertainties surrounding the timing and amount of future capital needs[194] - The company’s ability to generate revenues will depend on successful commercialization efforts by its partners and the market acceptance of its products[193] Workforce and Organizational Changes - A reduction in force was announced on November 1, 2023, expected to reduce the workforce by approximately 30%, with anticipated severance and related benefits costs of about $7.0 million[109] - The company plans to implement a further reduction of its workforce by approximately 30% to prioritize key research and development programs[202]

Financial Performance - Total current assets decreased from $295,080,000 in December 2022 to $172,320,000 in June 2023, a decline of approximately 41.5%[17] - Cash and cash equivalents dropped from $92,942,000 in December 2022 to $45,898,000 in June 2023, representing a decrease of about 50.7%[17] - The company reported a total accumulated deficit of $1,838,903,000 as of June 30, 2023, up from $1,693,024,000 in December 2022, indicating an increase in losses[19] - Total revenue for the three months ended June 30, 2023, was $957,000, compared to $51,579 for the same period in 2022, representing a significant increase[22] - The company reported a net loss of $71,108,000 for the six months ended June 30, 2023, compared to a net loss of $69,639,000 for the same period in 2022[22] - Net loss for the six months ended June 30, 2023, was $145.9 million, compared to a net loss of $69.6 million for the same period in 2022[26] - The company reported a gain on the sale of the ATOM Facility of $50,237,000 in the previous year, which significantly impacted the income before provision for income taxes[22] - The total accumulated deficit as of June 30, 2023, was $(1,838,903,000), indicating the ongoing financial challenges faced by the company[24] Research and Development - The company is early in its development efforts, with only a small number of product candidates in clinical development, while others remain in preclinical stages[15] - The company is focused on the commercialization of Ebvallo™ in the UK and EU, with potential milestone and royalty payments under its agreement with Pierre Fabre Medicament[11] - The company is advancing the development of ATA3219, an allogeneic CAR T therapy targeting B-cell malignancies, with plans to start a Phase 1 study in the coming months[124] - The Phase 2 study of ATA188 is expected to include over 90 patients, with data on confirmed disability improvement planned for early November 2023[123] - The company is conducting an open-label, single-arm Phase 1 clinical study of ATA2271 for patients with advanced mesothelioma[126] - The company is developing ATA3431, a multi-targeted allogeneic CAR T immunotherapy targeting B-cell malignancies, and collaborating on a next-generation EBV vaccine[127] - Atara's most advanced T-cell immunotherapy, tab-cel (tabelecleucel), has received marketing authorization in the EU and UK and is in Phase 3 development in the US[30] - Tab-cel has received Breakthrough Therapy Designation in the U.S. for the treatment of EBV+ PTLD after hematopoietic cell transplants[121] Commercialization and Revenue - The company has limited commercialization revenues to date and may never achieve profitability[15] - Commercialization revenue was $0.8 million and $1.7 million for the three and six months ended June 30, 2023, respectively, due to the EC marketing authorization for Ebvallo being transferred to Pierre Fabre in February 2023[146] - License and collaboration revenues decreased to $0.2 million and $0.5 million for the three and six months ended June 30, 2023, compared to $51.6 million and $58.9 million for the same periods in 2022, primarily due to the termination of the Bayer Agreements[147] - The company is entitled to receive up to $308 million in remaining milestone payments and double-digit tiered royalties from Ebvallo sales, subject to specific conditions[53] - The company received a $30 million milestone payment in September 2022 related to the Pierre Fabre Commercialization Agreement, following European Commission approval of Ebvallo[51] - An additional $40 million in milestone payments was received in January 2023 upon meeting certain regulatory milestones[53] Operating Expenses - Research and development expenses for the six months ended June 30, 2023, were $118,297,000, down from $139,861,000 in the same period of 2022, indicating a reduction of approximately 15.5%[22] - The company had total costs and operating expenses of $148,615,000 for the six months ended June 30, 2023, compared to $179,245,000 for the same period in 2022, reflecting a decrease of about 17.1%[22] - General and administrative expenses were $13.3 million and $27.2 million for the three and six months ended June 30, 2023, down from $18.8 million and $39.4 million in 2022, mainly due to lower payroll costs following a reduction in force[156] - Stock-based compensation expense for the six months ended June 30, 2023, was $24,316,000, compared to $14,335,000 for the same period in 2022, showing an increase of approximately 69.5%[24] Cash Flow and Financing - The company expects to require substantial additional financing to achieve its goals, with a failure to obtain necessary capital potentially delaying or terminating product development efforts[15] - The company plans to secure additional capital through public or private offerings and has $55.2 million remaining under its 2021 ATM Facility[35] - Net cash used in operating activities decreased to $91.2 million for the six months ended June 30, 2023, from $148.5 million in the prior year[26] - The company has raised capital in the past but faces uncertainty in obtaining sufficient funding on acceptable terms for ongoing operations[192] - Existing cash and short-term investments are expected to fund operations only into the second quarter of 2024, raising doubts about the company's ability to continue as a going concern[171] - The company anticipates needing to raise substantial additional funding to finance planned operations and product development[172] Risks and Challenges - The company faces risks related to the lengthy and expensive clinical drug development process, which has uncertain outcomes[15] - The approval process for product candidates is unpredictable and may take many years, with the company facing challenges due to the novel nature of its therapies[206] - The company may face significant delays in clinical trials due to health epidemics and pandemics, impacting patient enrollment and site operations[203] - The company may need to relinquish rights to product candidates or grant licenses on unfavorable terms if additional funding is required[193] - The ability to generate revenues and achieve profitability is contingent on successful commercialization efforts by partners and market acceptance of products[188]

Financial Performance - Total revenue for Q1 2023 was $1.226 million, a decrease of 83.2% compared to $7.314 million in Q1 2022[20] - Net loss for Q1 2023 was $74.771 million, compared to a net loss of $88.105 million in Q1 2022, indicating an improvement of 15.1%[20] - For the three months ended March 31, 2023, the net loss was $74.77 million, an improvement from a net loss of $88.10 million for the same period in 2022, representing a 15.0% decrease in losses[26] - Cash, cash equivalents, and restricted cash at the end of the period were $48.89 million, down from $103.02 million at the end of March 31, 2022, indicating a decrease of 52.6% year-over-year[26] - The company reported commercialization revenue of $884,000 in Q1 2023, compared to no revenue in Q1 2022[20] - License and collaboration revenue decreased to $0.3 million for the three months ended March 31, 2023, from $7.3 million in the same period in 2022, primarily due to the termination of agreements with Bayer AG[143] - The company has a significant accumulated deficit of $1.768 billion as of March 31, 2023[17] Cash and Liquidity - Cash and cash equivalents decreased to $48.741 million as of March 31, 2023, from $92.942 million at the end of 2022[15] - The company expects that existing cash and short-term investments as of March 31, 2023, will not be sufficient to fund planned operations for at least the next twelve months, raising substantial doubt about its ability to continue as a going concern[34] - The company expects existing cash and short-term investments to fund operations into Q2 2024 but anticipates needing additional capital for the next twelve months[164] - The company plans to secure additional capital through public or private security offerings, utilizing the remaining $55.2 million from its 2021 ATM Facility, and seeking a commercialization partner for tab-cel in the U.S. to alleviate substantial doubt about its ability to continue as a going concern for at least 12 months[35] Research and Development - Research and development expenses for Q1 2023 were $62.156 million, down from $74.963 million in Q1 2022, reflecting a reduction of 17.2%[20] - Total research and development expenses were $62.2 million in Q1 2023, down from $75.0 million in Q1 2022, reflecting a decrease of $12.8 million[149] - The company plans to continue investment in the development of product candidates, including ongoing Phase 3 clinical studies and next-generation CAR T programs[134] - The company is focused on advancing its product candidates and expects to require substantial additional financing to achieve its goals[13] Commercialization Efforts - The company has entered into a commercialization agreement with Pierre Fabre for the distribution of tab-cel in Europe and select emerging markets[29] - The company received a $30 million milestone payment from Pierre Fabre following the European Commission's approval of Ebvallo for EBV+ PTLD, with an additional $40 million milestone payment received in January 2023[50][52] - The marketing authorization for Ebvallo was transferred to Pierre Fabre in February 2023, with progressive launches planned[120] - The company is engaged in discussions with potential partners for the commercialization of tab-cel in the U.S.[120] Workforce and Restructuring - The company recorded restructuring charges of $6.0 million due to a workforce reduction of approximately 20% to focus on research and development[72] - The company reduced its workforce by approximately 20% in August 2022 to prioritize key research and development programs[189] Regulatory and Clinical Development - Tab-cel (tabelecleucel) has received marketing authorization approval in the EU and is currently in Phase 3 clinical development in the U.S. for EBV+ PTLD[112] - ATA188, targeting EBV antigens for multiple sclerosis treatment, is in Phase 2 development with approximately 90 patients planned for the study[122] - The company may face challenges in obtaining regulatory approval for its product candidates due to the novel nature of T-cell immunotherapies and changing regulatory requirements[200] - The FDA may require additional clinical data or trials for the approval of tab-cel, potentially delaying commercialization plans[203] Risks and Uncertainties - The company acknowledges that raising additional capital may cause dilution to existing stockholders and restrict operations[187] - The company has incurred substantial losses since inception and anticipates continuing to incur significant operating losses for the foreseeable future[175] - The company may experience delays in clinical trials due to health epidemics, including the COVID-19 pandemic, affecting patient enrollment and site operations[197] - Regulatory approvals may contain significant limitations, such as use restrictions or post-approval study requirements, affecting market potential[205]